Perioperative medicine & outcomes
Remimazolam vs. propofol for prevention of postoperative nausea and vomiting in laparoscopic gynecological surgery: a randomized non-inferiority trial
Authors' conclusion
Although non-inferiority of remimazolam to propofol for PONV prevention was not demonstrated in this high-risk population, remimazolam provided a superior safety profile, with significantly reduced injection pain and improved hemodynamic stability.
Study context
- Population
- Women aged 18–65 years, American Society of Anesthesiologists (ASA) I–III, undergoing elective laparoscopic gynecological surgery326 per-protocol
- Participants
- 334 women
- Comparison
- Remimazolam vs propofol for anaesthesia induction and maintenance
- Primary endpoint
- Incidence of PONV
- Follow-up
- 24 h
Methodological detailssingle-centre, prospective, double-blind, non-inferiority
- Single-centre
- Prospective
- Double-blind
- Non-inferiority
Primary result
As reported in the abstract
Secondary outcomes
Rescue antiemetics, postoperative nausea and vomiting (PONV) types, postoperative pain scores, patient satisfaction
- No significant differences
Safety
Injection pain
P < 0.001
Hypotension · within 10 min after induction
P = 0.013
Intraoperative bradycardia
P < 0.001
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Remimazolam vs. propofol for prevention of postoperative nausea and vomiting in laparoscopic gynecological surgery: a randomized non-inferiority trial. Perioper Med (Lond). Published 16 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →